Spots Global Cancer Trial Database for transitional cell carcinoma of the bladder
Every month we try and update this database with for transitional cell carcinoma of the bladder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | NCT00380029 | Bladder Cancer | Erlotinib Radical Cystect... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract | NCT00014144 | Bladder Cancer Transitional Ce... Urethral Cancer | gefitinib | - | SWOG Cancer Research Network | |
| Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter | NCT00066352 | Bladder Cancer Transitional Ce... | bortezomib | 18 Years - | University Health Network, Toronto | |
| Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | NCT01687244 | Superficial Bla... | INSTILADRIN | 18 Years - | FKD Therapies Oy | |
| Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer | NCT00003342 | Bladder Cancer Transitional Ce... | filgrastim carboplatin doxorubicin hyd... gemcitabine hyd... paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | NCT00024349 | Bladder Cancer | fluorouracil mitomycin C radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy | NCT00066612 | Bladder Cancer Transitional Ce... Urethral Cancer | irinotecan hydr... | 18 Years - | SWOG Cancer Research Network | |
| Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer | NCT01824329 | Bladder Cancer Transitional Ce... | Prostate capsul... Nerve sparing c... | 18 Years - | University of Michigan | |
| 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder | NCT01124682 | Bladder Cancer | diagnostic cyst... diffusion-weigh... implanted fiduc... quality-of-life... 3-dimensional c... image-guided ra... selective exter... | 18 Years - | National Cancer Institute (NCI) | |
| Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00003725 | Bladder Cancer | valrubicin conventional su... | 18 Years - | National Cancer Institute (NCI) | |
| S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium | NCT00045630 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin gemcitabine paclitaxel surgery | 18 Years - | SWOG Cancer Research Network | |
| Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer | NCT00792025 | Bladder Cancer Transitional Ce... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | NCT00627432 | Bladder Cancer | gemcitabine hyd... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00445601 | Bladder Cancer | gemcitabine hyd... placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer | NCT00003642 | Bladder Cancer | cisplatin fluorouracil radiation thera... | - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | NCT00024349 | Bladder Cancer | fluorouracil mitomycin C radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | NCT00380029 | Bladder Cancer | Erlotinib Radical Cystect... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer | NCT00033436 | Bladder Cancer | niacinamide carbogen radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer | NCT00003642 | Bladder Cancer | cisplatin fluorouracil radiation thera... | - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | NCT01191892 | Bladder Cancer Transitional Ce... Ureter Cancer Urethral Cancer | carboplatin gemcitabine hyd... vandetanib Placebo | 18 Years - 120 Years | Cardiff University | |
| Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function | NCT00478361 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | Gemcitabine hyd... Paclitaxel Doxorubicin hyd... Pegfilgrastim | - | M.D. Anderson Cancer Center | |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | NCT02897765 | Urinary Bladder... Bladder Tumors Transitional Ce... Malignant Melan... Melanoma Skin Cancer Carcinoma, Non-... Lung Cancer | NEO-PV-01 Nivolumab Adjuvant | 18 Years - | BioNTech SE | |
| Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | NCT00088946 | Bladder Cancer | Polyphenon E erlotinib hydro... Erlotinib place... Polyphenon E | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | NCT00003640 | Bladder Cancer | filgrastim cisplatin doxorubicin hyd... methotrexate vinblastine sul... surgical proced... radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer | NCT00088946 | Bladder Cancer | Polyphenon E erlotinib hydro... Erlotinib place... Polyphenon E | 18 Years - | Jonsson Comprehensive Cancer Center | |
| BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer | NCT00004122 | Bladder Cancer | BCG vaccine recombinant int... | 18 Years - | Roswell Park Cancer Institute | |
| Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery | NCT00777491 | Bladder Cancer | induction cispl... induction 5-flu... induction gemci... Induction BID r... Induction QD ra... Consolidation B... Consolidation Q... consolidation g... consolidation 5... consolidation c... radical cystect... Post-Induction ... adjuvant gemcit... adjuvant cispla... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | NCT00268450 | Bladder Cancer | bevacizumab cisplatin gemcitabine hyd... paclitaxel cysectomy | 18 Years - 120 Years | Medical University of South Carolina | |
| A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine | NCT02101931 | Transitional Ce... | Amino levulinic... | - | Princess Al-Johara Al-Ibrahim Cancer Research Center | |
| Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium | NCT00003376 | Bladder Cancer Transitional Ce... Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium | NCT00028756 | Stage III Bladd... Stage IV Bladde... Transitional Ce... | doxorubicin hyd... gemcitabine hyd... vinblastine sul... methotrexate cisplatin filgrastim | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer | NCT00004122 | Bladder Cancer | BCG vaccine recombinant int... | 18 Years - | Roswell Park Cancer Institute | |
| Combination Chemotherapy in Treating Patients With Bladder Cancer | NCT00003701 | Bladder Cancer Urethral Cancer | carboplatin cisplatin doxorubicin hyd... methotrexate paclitaxel vinblastine sul... | 0 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery | NCT01108003 | Recurrent Bladd... Stage 0 Bladder... Stage I Bladder... Stage II Bladde... Transitional Ce... | broccoli sprout... laboratory biom... Mango Juice | 18 Years - | Roswell Park Cancer Institute | |
| Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | NCT00268450 | Bladder Cancer | bevacizumab cisplatin gemcitabine hyd... paclitaxel cysectomy | 18 Years - 120 Years | Medical University of South Carolina | |
| Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | NCT00021099 | Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ixabepilone | 18 Years - | National Cancer Institute (NCI) | |
| Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer | NCT01196403 | Bladder Cancer | questionnaire a... quality-of-life... robot-assisted ... therapeutic con... therapeutic lap... | 18 Years - | National Cancer Institute (NCI) | |
| BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer | NCT00352079 | Bladder Cancer | BCG vaccine gefitinib quality-of-life... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer | NCT00981656 | Bladder Cancer | cisplatin 5-fluorouracil Mitomycin Three-Dimension... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
| Chemotherapy in Treating Patients With Early-Stage Bladder Cancer | NCT00003129 | Bladder Cancer | valrubicin | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | NCT01828736 | Recurrent Bladd... Stage IV Bladde... Transitional Ce... | Trastuzumab Gemcitabine Carboplatin Cisplatin | 18 Years - 80 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | NCT00005958 | Bladder Cancer Transitional Ce... | filgrastim docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | NCT01118039 | Bladder Cancer Transitional Ce... Urethral Cancer | sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life... | 18 Years - | National Cancer Institute (NCI) | |
| Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC | NCT00859339 | Transitional Ce... | Gemcitabine Cisplatin Sunitinib Malat... Radical Cystect... | 18 Years - | Hoosier Cancer Research Network | |
| Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder | NCT00084578 | Bladder Cancer | celecoxib rosiglitazone m... conventional su... neoadjuvant the... | 18 Years - | Fox Chase Cancer Center | |
| Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | NCT00005958 | Bladder Cancer Transitional Ce... | filgrastim docetaxel gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| BCG With or Without Mitomycin in Treating Patients With Bladder Cancer | NCT00023842 | Bladder Cancer | BCG vaccine mitomycin C adjuvant therap... conventional su... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | NCT03081858 | Bladder Cancer ... Non-Muscle Inva... Bladder Cancer Urinary Bladder Transitional Ce... Urinary Bladder... Urologic Neopla... Urogenital Neop... Urinary Bladder... Urologic Diseas... | TSD-001 | 18 Years - 85 Years | Lipac Oncology LLC | |
| Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | NCT00089128 | Bladder Cancer | gemcitabine hyd... irinotecan hydr... | 18 Years - 120 Years | Medical University of South Carolina | |
| Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma | NCT01828736 | Recurrent Bladd... Stage IV Bladde... Transitional Ce... | Trastuzumab Gemcitabine Carboplatin Cisplatin | 18 Years - 80 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab | NCT03263039 | Transitional Ce... Biomarkers | Pembrolizumab | 18 Years - | Erasmus Medical Center | |
| Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab | NCT03263039 | Transitional Ce... Biomarkers | Pembrolizumab | 18 Years - | Erasmus Medical Center | |
| Gene Therapy in Treating Patients With Advanced Bladder Cancer | NCT00003167 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... Stage IV Bladde... Transitional Ce... | Ad5CMV-p53 gene | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer | NCT00002490 | Bladder Cancer | BCG vaccine mitomycin C radiation thera... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer | NCT01224665 | Bladder Cancer | therapeutic con... therapeutic sta... therapeutic ext... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer | NCT00003175 | Bladder Cancer Transitional Ce... Urethral Cancer | fluorouracil | - | National Cancer Institute (NCI) | |
| Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer | NCT00054626 | Bladder Cancer | cisplatin gemcitabine hyd... adjuvant therap... | 18 Years - 74 Years | National Cancer Institute (NCI) | |
| Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | NCT01382706 | Recurrent Bladd... Stage III Bladd... Stage IV Bladde... Transitional Ce... | docetaxel lapatinib ditos... immunohistochem... fluorescence in... laboratory biom... | 18 Years - | University of Southern California | |
| Adjuvant Radiation for High Risk Bladder Cancer | NCT01954173 | Bladder Cancer Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... | 3D conformal ra... | 18 Years - | Emory University | |
| Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | NCT02318329 | Advanced Solid ... Gastric Cancer Transitional Ce... | FPA144 | 18 Years - | Five Prime Therapeutics, Inc. | |
| Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) | NCT01089088 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... sunitinib malat... | 16 Years - 120 Years | Cardiff University | |
| Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | NCT01687244 | Superficial Bla... | INSTILADRIN | 18 Years - | FKD Therapies Oy | |
| Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer | NCT00623064 | Bladder Cancer Transitional Ce... | cisplatin gemcitabine hyd... lapatinib ditos... pharmacological... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Paclitaxel in Treating Patients With Early-Stage Bladder Cancer | NCT00002917 | Bladder Cancer | paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants | NCT00900276 | Bladder Cancer Kidney Cancer Transitional Ce... Urethral Cancer | immunologic tec... laboratory biom... mass spectromet... | 18 Years - 120 Years | Wake Forest University Health Sciences | |
| 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer | NCT01162785 | Bladder Cancer | SCH 721015 | 18 Years - | M.D. Anderson Cancer Center | |
| Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer | NCT00095589 | Bladder Cancer | loss of heteroz... microarray anal... microsatellite ... cytology specim... laboratory biom... computed tomogr... cystoscopy | 40 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer | NCT00004223 | Bladder Cancer Transitional Ce... Urethral Cancer | docetaxel gemcitabine hyd... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer | NCT00553345 | Bladder Cancer | selenium vitamin E chemoprevention | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | NCT01090466 | Bladder Cancer Transitional Ce... Urethral Cancer | cisplatin gemcitabine hyd... temsirolimus pharmacological... | 16 Years - 120 Years | Cardiff University | |
| S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | NCT00445601 | Bladder Cancer | gemcitabine hyd... placebo | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function | NCT00005644 | Bladder Cancer Transitional Ce... Urethral Cancer | gemcitabine hyd... paclitaxel | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | NCT00112671 | Metastatic Tran... Recurrent Bladd... Recurrent Trans... Regional Transi... Stage III Bladd... Stage IV Bladde... Transitional Ce... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer | NCT00028860 | Bladder Cancer Transitional Ce... | filgrastim carboplatin gemcitabine hyd... ifosfamide paclitaxel adjuvant therap... | - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
